GlaxoSmithKline Stock To Go Ex-dividend Tomorrow (GSK)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- The ex-dividend date for GlaxoSmithKline (NYSE: GSK) is tomorrow, November 14, 2012. Owners of shares as of market close today will be eligible for a dividend of 58 cents per share. At a price of $42.83 as of 9:30 a.m. ET, the dividend yield is 5.3%.

The average volume for GlaxoSmithKline has been two million shares per day over the past 30 days. GlaxoSmithKline has a market cap of $109.95 billion and is part of the health care sector and drugs industry. Shares are down 4.6% year to date as of the close of trading on Monday.

GlaxoSmithKline plc, together with its subsidiaries, engages in the discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health-related consumer products worldwide. The company has a P/E ratio of 13.1, below the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. You can view the full GlaxoSmithKline Ratings Report.

See our dividend calendar or top-yielding stocks list.

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.
null

If you liked this article you might like

These Stocks Pay You to Own Them

Nascar Champ Danica Patrick--'I'm Not That Into Cars'

Nascar Driver Danica Patrick Says 'I'm Not a Car Person'

Hikma Sinks on Advair Generic Concerns

Shire Gains as it Seeks European Approval For Dry Eye Treatment